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IrritabilityBehavioral symptoms are known side effects of levetiracetam. Previous case series in children and adolescents
have demonstrated the potential effect of pyridoxine in ameliorating these symptoms. We retrospectively
reviewed the charts of 51 patients treatedwith pyridoxine to control agitation and irritability following the intro-
duction of levetiracetam. These symptoms were relieved in 34 patients (66.6%). Seventeen patients did not ap-
pear to beneﬁt from this supplementation. This preliminary study suggests that pyridoxine might be an
effective option across all ages for patients suffering from levetiracetam-induced behavioral side effects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Levetiracetam (LEV) is an antiepileptic drug that is approved for use
as adjunct treatment for partial epilepsy in patients aged 4 years and
older, as well as for juvenile myoclonic epilepsy in patients aged
12 years and older [1,2]. Irritability and agitation are known behavioral
side effects of LEV, and it is reported in almost 13% of patients across
all age groups. Levetiracetam use can be associated with insomnia,
agitation, anxiety, emotional lability, and hyperactivity. Some of these
adverse events, however, are reported in patients with preexisting
behavioral issues [3]. Furthermore, these adverse effects can lead to
LEV discontinuation in a small percentage of patients [4]. Previous case
series from children and adolescents have indicated that pyridoxine
(vitamin B6) can alleviate behavioral side effects related to the use of
LEV [5,6]. The effect seems to be modest.
In this study,we sought to explore the potential beneﬁts of pyridoxine
supplementation for the treatment of behavioral side effects induced by
LEV in our patients attending the epilepsy clinic.erms of the Creative Commons
icense, which permits non-
edium, provided the original
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We retrospectively reviewed our electronic medical records to
identify all patients attending our epilepsy clinic and being treated
with both LEV and pyridoxine. Fifty-one adult patients were identiﬁed
using pyridoxine supplementation for the management of either irrita-
bility or agitation following the introduction of LEV. Age, gender, epilep-
sy classiﬁcation, duration of seizures, dosages of LEV and pyridoxine,
and the effect of the addition of pyridoxine on behavioral symptoms
were carefully analyzed.When in doubt, these patients were contacted.
This study was approved by the local institutional review board.
3. Results
This group comprised 41 men and 47 women. Their average age
was 34.2 years (SD = 11.1). The epilepsy was classiﬁed as idiopathic
in 15 patients (29.5%) and as partial in 36 (70.5%). Levetiracetammono-
therapy was used for 26 patients; the others were taking an average of
two additional antiepileptic drugs. The average daily dose of LEV was
2208 mg. Pyridoxine was started at 50 mg/day, and if no or partial ben-
eﬁt was noted, the dosewas increased to 100mg/day. However, the av-
erage dose to control the behavioral symptoms in our study was 54.5
mg/day (SD = 18.2). Most patients had reported behavioral problems
within the ﬁrst weeks after the addition of LEV. None of our patients,
however, had preexisting behavioral issues prior to the use of LEV.
None of the patients who did not receive pyridoxine supplementation
reported any signiﬁcant improvement in behavioral symptoms
throughout the course of treatment with LEV. On average, the effectsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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On a separate note, none of the patients who received pyridoxine
supplementation reported any signiﬁcant improvement in seizure fre-
quency throughout the course of treatment with LEV.4. Discussion
To our knowledge, this is the ﬁrst study that suggests a possible
beneﬁt of pyridoxine supplementation in the treatment of LEV-
induced behavioral side effects in the adult population. Previous reports
in the pediatric population have demonstrated the potential beneﬁcial
effect of pyridoxine to control the LEV-induced behavioral symptoms.
Miller [7] was able to control the behavioral disturbances caused by
LEV completely, in 5 of 6 children aged between 2 and 10 years, by
supplementing pyridoxine at an average dose of 7mg/kg/day. In another
study to examine the use of pyridoxine, Major et al. [8] analyzed
42 pediatric patients who had been treated with LEV and pyridoxine.
Twenty-two patients started pyridoxine after being on LEV, due to
behavioral side effects, and signiﬁcant behavioral improvement was
observed in nine (41%), no effect in eight (36%), deterioration in four
(18%), and an uncertain effect in one. The effects of pyridoxine supple-
mentation, similar to our study, were observed during the ﬁrst week
of its introduction.
Our study used a retrospective, chart review method and lacked a
placebo-controlled approach. Our results demonstrated that 66% of
patients who started pyridoxine after being on LEV had a signiﬁcant
behavioral improvement, and in the remaining one-third, pyridoxine
was not helpful in preventing LEV-related behavioral side effects.
Interestingly, and similar to previous reports in pediatric populations,
the improvement occurred during the ﬁrst few weeks after pyridoxine
supplementation, probably supporting its potential effect.
Pyridoxine is a water-soluble cofactor in more than 100 enzyme-
catalyzed reactions in the body, includingmany involved in the synthesis
or catabolism of neurotransmitters. There is no known pharmacokinetic
or pharmacodynamic interaction between LEV andpyridoxine that could
explain its potential clinical beneﬁt. On that note, it can be said that the
underlying mechanism(s) that would explain its efﬁcacy in controlling
the behavioral adverse effects of LEV is largely unknown, and its recom-
mended use to control these symptoms is empirical at best. Similarly,
pyridoxine, based on empirical grounds, has been used to treat other
medical conditions such as premenstrual depression [9]. On the
other hand, pyridoxine has been tried based on our current under-
standing for treatment of other underlying metabolic disorders. For
example, pyridoxine-dependent epilepsy, a rare autosomal recessive
error of metabolism characterized by neonatal seizures, responds to
pyridoxine. Intravenous administration of 50–100 mg of pyridoxinepromptly controls the seizures, but lifelong supplementation is
required (5–300 mg/kg/day) [10].
The average dose to control the behavioral symptoms in our study
was less than 100 mg/day. This dose is considered quite safe. Toxicity
of this supplementation tends to occur at a dose higher than 1000 mg/
day [11,12]. Our study recommended doses much lower than the toxic
threshold. Indeed, none of our patients had signs of toxicity, including
neuropathy.
We realize the limitation of our study, being retrospective and from
a single center. However, this preliminary study suggests that pyridox-
ine might be used safely to control LEV- induced behavioral side effects
in adults. Whether vitamin B6 has the same efﬁcacy in controlling be-
havioral symptoms in patients with epilepsy in general or it shows the
same efﬁcacy in those patients who are treated with other AEDs re-
mains to be carefully examined. A prospective, placebo-controlled
study is needed to conﬁrmourﬁnding and to address these unanswered
questions.
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